Bradley J Quade

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/555841/publications.pdf

Version: 2024-02-01

30 papers 1,330 citations

16 h-index 501196 28 g-index

31 all docs

31 docs citations

times ranked

31

1754 citing authors

#	Article	IF	CITATIONS
1	SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. Modern Pathology, 2020, 33, 2092-2103.	5.5	211
2	Perivascular Epithelioid Cell Neoplasm (PEComa) of the Gynecologic Tract. American Journal of Surgical Pathology, 2014, 38, 176-188.	3.7	165
3	The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecologic Oncology, 2014, 132, 360-365.	1.4	133
4	HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes and Cancer, 1999, 25, 316-322.	2.8	125
5	Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecologic Oncology, 2014, 132, 280-286.	1.4	74
6	Intravenous leiomyomatosis: an unusual intermediate between benign and malignant uterine smooth muscle tumors. Modern Pathology, 2016, 29, 500-510.	5.5	65
7	Frequent Loss of Heterozygosity for Chromosome 10 in Uterine Leiomyosarcoma in Contrast to Leiomyoma. American Journal of Pathology, 1999, 154, 945-950.	3.8	64
8	The Role of Endometrial Biopsy in the Preoperative Detection of Uterine Leiomyosarcoma. Journal of Minimally Invasive Gynecology, 2016, 23, 567-572.	0.6	51
9	Uterine Polyps With Features Overlapping With Those of Mýllerian Adenosarcoma. American Journal of Surgical Pathology, 2015, 39, 116-126.	3.7	50
10	Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata., 1998, 23, 361-366.		45
11	Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (<scp>STUMP</scp>): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters. Histopathology, 2018, 73, 284-298.	2.9	45
12	<scp>GATA</scp> 3 expression in gestational trophoblastic tissues and tumours. Histopathology, 2015, 67, 636-644.	2.9	39
13	Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour. Histopathology, 2017, 70, 1138-1146.	2.9	38
14	Prenatal sonography in trisomy 9. Prenatal Diagnosis, 1992, 12, 175-181.	2.3	31
15	Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model. Modern Pathology, 2014, 27, 569-579.	5.5	31
16	Meningeal carcinomatosis from transitional cell carcinoma of the bladder. Cancer, 1993, 72, 553-557.	4.1	30
17	Risk Factors for Occult Uterine Sarcoma Among Women Undergoing Minimally Invasive Gynecologic Surgery. Journal of Minimally Invasive Gynecology, 2016, 23, 34-39.	0.6	19
18	Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression. American Journal of Obstetrics and Gynecology, 2021, 224, 372.e1-372.e30.	1.3	16

#	Article	IF	CITATIONS
19	Epithelioid Leiomyosarcoma of the Uterus. American Journal of Surgical Pathology, 2022, 46, 464-475.	3.7	16
20	Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecologic Oncology, 2018, 148, 5-11.	1.4	15
21	Third trimester stillbirth during the first wave of the SARS-CoV-2 pandemic: Similar rates with increase in placental vasculopathic pathology. Placenta, 2021, 109, 72-74.	1.5	15
22	Loss of <i>LDAH</i> associated with prostate cancer and hearing loss. Human Molecular Genetics, 2018, 27, 4194-4203.	2.9	14
23	Clinical, pathologic, cytogenetic, and molecular profiling in self-identified black women with uterine leiomyomata. Cancer Genetics, 2018, 222-223, 1-8.	0.4	12
24	Clinicopathological and immunohistochemical features of uterine adenomyomatous polyps. Human Pathology, 2019, 84, 239-245.	2.0	11
25	A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases. Modern Pathology, 2022, 35, 794-807.	5.5	6
26	Hereditary leiomyomatosis and renal cell cancer: Cutaneous lesions & amp; atypical fibroids. Case Reports in Women's Health, 2017, 15, 31-34.	0.5	3
27	Endometrial cancer with an EML4-ALK rearrangement. Journal of Physical Education and Sports Management, 2018, 4, a003020.	1.2	3
28	HMGIC expression in human adult and fetal tissues and in uterine leiomyomata., 1999, 25, 316.		1
29	HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes and Cancer, 1999, 25, 316-322.	2.8	1
30	From GWAS to Therapy: Fatty Acid Synthase in Uterine Leiomyomata. FASEB Journal, 2015, 29, 147.5.	0.5	1